drugset / Trial / NCT02131753
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.
Timeline
- Start
- 2004-05
- Primary completion
- 2025-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 0.14 mg/kg | Subcutaneous |